The price of Avalo Therapeutics Inc (NASDAQ:AVTX) shares last traded on Wall Street fell -4.11% to $0.09.
Based on available information, 1 analysts follow Avalo Therapeutics Inc (NASDAQ:AVTX). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $0.75 and a low of $0.75, we find $0.75. Given the previous closing price of $0.09, this indicates a potential upside of 733.33 percent. AVTX stock price is now -31.23% away from the 50-day moving average and -94.11% away from the 200-day moving average. The market capitalization of the company currently stands at $16.60M.
Among analysts, 1 rate the stock a hold while 0 rate it a buy. Brokers who have rated the stock have averaged $0.75 as their price target over the next twelve months.
With the price target of $6, RBC Capital Mkts recently initiated with Outperform rating for Avalo Therapeutics Inc (NASDAQ: AVTX).
In other news, ARMISTICE CAPITAL, LLC, 10% Owner sold 937,404 shares of the company’s stock on Jun 27. The stock was sold for $486,888 at an average price of $0.52. Upon completion of the transaction, the 10% Owner now directly owns 731,458 shares in the company, valued at $65831.22. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 26, 10% Owner ARMISTICE CAPITAL, LLC sold 2,746,138 shares of the business’s stock. A total of $1,682,010 was realized by selling the stock at an average price of $0.61. This leaves the insider owning 1,668,862 shares of the company worth $0.15 million. Insiders disposed of 2,545,404 shares of company stock worth roughly $0.23 million over the past 1 year. A total of 0.22% of the company’s stock is owned by insiders.
A candlestick chart of Avalo Therapeutics Inc (NASDAQ: AVTX) showed a price of $0.0896 on Monday morning. During the past 12 months, Avalo Therapeutics Inc has had a low of $0.08 and a high of $6.09. As of last week, the company has a debt-to-equity ratio of 0.14, a current ratio of 2.11, and a quick ratio of 2.11. The fifty day moving average price for AVTX is $0.1256 and a two-hundred day moving average price translates $1.4660 for the stock.
The latest earnings results from Avalo Therapeutics Inc (NASDAQ: AVTX) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.11, beating analysts’ expectations of -$1.1 by 0.99. This compares to $0.34 EPS in the same period last year. The net profit margin was -1475.02% and return on equity was -524.01% for AVTX. The company reported revenue of $0.24 million for the quarter, compared to $14.95 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -98.42 percent. For the current quarter, analysts expect AVTX to generate $300k in revenue.